New Breast Cancer Drugs May Beat Tamoxifen
Cancer Group OK's Arimidex, Aromasin, Femara to Prevent Recurrence
WebMD News Archive
Lower Recurrent Breast Cancer, Side Effect Risk continued...
Some doctors, Buzdar says, think there may be a long-term benefit to starting with tamoxifen, then switching to one of the new breast cancer drugs. But he believes the new drugs offer a woman her best chance of remaining cancer-free after surgery.
"The most important thing breast cancer patients should ask their doctors is why they are on tamoxifen and not on aromatase inhibitors," Buzdar says.
But there still are very good reasons to start with tamoxifen, says Carl Kardinal, MD, director of clinical research at the Ochsner Clinic Foundation in New Orleans.
"Tamoxifen has been around for more than 30 years. We know the side effects. The newer aromatase drugs, we don't really know yet," Kardinal tells WebMD. "Another issue which is very important is the cost. Tamoxifen is now available as a generic drug, and costs in the range of $40-$45 a month. Aromatase inhibitors like Arimidex and Femara cost more than $200 a month."